Role of the Dorsomedial Hypothalamus in Mediating the Response to Benzodiazepines on Trial 2 in the Elevated Plus-Maze Test of Anxiety

被引:0
|
作者
Sandra E File
Luis E Gonzalez
Rachael Gallant
机构
[1] Psychopharmacology Research Unit,
[2] Neuroscience Research Centre,undefined
[3] GKT School of Biomedical Sciences,undefined
[4] King's College London,undefined
来源
Neuropsychopharmacology | 1999年 / 21卷
关键词
Anxiety; Phobia; Hypothalamus; Benzodiazepines; Emotional Memory; Plus-maze;
D O I
暂无
中图分类号
学科分类号
摘要
Trial 2 in the elevated plus-maze provides an animal model of specific phobia (fear of heights). On this trial, rats no longer respond to benzodiazepines. The present experiment examined the role of the dorsomedial hypothalamus in mediating insensitivity to chlordiazepoxide on trial 2. Rats received a 5 min exposure to the maze, undrugged. Forty-eight hours later, rats injected with control infusions into the dorsomedial hypothalamus showed the usual lack of response to chlordiazepoxide (5 mg/kg, i.p.). However, those receiving lidocaine injections (40 μg/μl in a volume of 0.2 μl) in the dorsomedial hypothalamus (producing functional inactivation), immediately before trial 2, responded with an anxiolytic response to chlordiazepoxide, characterised by an increased percentage of time on the open arms and by an increased number of entries into, and time spent on, the distal portions of the open arms. Since the lidocaine injections were without anxiolytic effects, our results suggest that this region of the hypothalamus regulates the functional state of benzodiazepine receptors in other brain regions.
引用
收藏
页码:312 / 320
页数:8
相关论文
共 50 条
  • [21] Anxiety conditioned to nicotine in the elevated plus-maze is time dependent
    Tucci, S
    Cheeta, S
    Genn, RF
    Seth, P
    File, SE
    BEHAVIOURAL PHARMACOLOGY, 2002, 13 (08): : 615 - 620
  • [22] Estrous cycle influences the response of female rats in the elevated plus-maze test
    Marcondes, FK
    Miguel, KJ
    Melo, LL
    Spadari-Bratfisch, RC
    PHYSIOLOGY & BEHAVIOR, 2001, 74 (4-5) : 435 - 440
  • [23] FACTOR-ANALYSIS OF SPATIOTEMPORAL AND ETHOLOGICAL MEASURES IN THE MURINE ELEVATED PLUS-MAZE TEST OF ANXIETY
    RODGERS, RJ
    JOHNSON, NJT
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1995, 52 (02) : 297 - 303
  • [24] Individual differences in the elevated plus-maze and the forced swim test
    Estanislau, Celio
    Ramos, Anna Carolina
    Ferraresi, Paula Daniele
    Costa, Naiara Fernanda
    Cotta Pires de Carvalho, Heloisa Maria
    Batistela, Silmara
    BEHAVIOURAL PROCESSES, 2011, 86 (01) : 46 - 51
  • [25] Role of δ-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats
    Akiyoshi Saitoh
    Yuji Yoshikawa
    Kenji Onodera
    Junzo Kamei
    Psychopharmacology, 2005, 182 : 327 - 334
  • [26] Role of δ-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats
    Saitoh, A
    Yoshikawa, Y
    Onodera, K
    Kamei, J
    PSYCHOPHARMACOLOGY, 2005, 182 (03) : 327 - 334
  • [27] Oxycodone decreases anxiety-like behavior in the elevated plus-maze test in male and female rats
    Bruijnzeel, Adriaan W.
    Behnood-Rod, Azin
    Malphurs, Wendi
    Chellian, Ranjithkumar
    Caudle, Robert M.
    Febo, Marcelo
    Setlow, Barry
    Neubert, John K.
    BEHAVIOURAL PHARMACOLOGY, 2022, 33 (06): : 418 - 426
  • [28] Aversion in the elevated plus-maze: Role of visual and tactile cues
    Filgueiras, Guilherrne Bracarense
    Carvalho-Netto, Eduardo F.
    Estanislau, Celio
    BEHAVIOURAL PROCESSES, 2014, 107 : 106 - 111
  • [29] Role of dorsal hippocampal cannabinoid receptors and nitric oxide in anxiety like behaviours in rats using the elevated plus-maze test
    Roohbakhsh, Ali
    Moghaddam, Akbar Hajizadeh
    Massoudi, Roohollah
    Zarrindast, Mohammad-Reza
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2007, 34 (03) : 223 - 229
  • [30] Effects of rolipram on the elevated plus-maze test in rats:: a preliminary study
    Silvestre, JS
    Fernández, AG
    Palacios, JM
    JOURNAL OF PSYCHOPHARMACOLOGY, 1999, 13 (03) : 274 - 277